127 related articles for article (PubMed ID: 34633770)
21. Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi.
Yeh I; Lang UE; Durieux E; Tee MK; Jorapur A; Shain AH; Haddad V; Pissaloux D; Chen X; Cerroni L; Judson RL; LeBoit PE; McCalmont TH; Bastian BC; de la Fouchardière A
Nat Commun; 2017 Sep; 8(1):644. PubMed ID: 28935960
[TBL] [Abstract][Full Text] [Related]
22. Epithelioid blue nevus: neoplasm Sui generis or variation on a theme?
Groben PA; Harvell JD; White WL
Am J Dermatopathol; 2000 Dec; 22(6):473-88. PubMed ID: 11190438
[TBL] [Abstract][Full Text] [Related]
23. Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus.
Zembowicz A; Carney JA; Mihm MC
Am J Surg Pathol; 2004 Jan; 28(1):31-40. PubMed ID: 14707861
[TBL] [Abstract][Full Text] [Related]
24. NGS-Based Analysis of Atypical Deep Penetrating Nevi.
Manca A; Sini MC; Cesinaro AM; Portelli F; Urso C; Lentini M; Cardia R; Alos L; Cook M; Simi S; Paliogiannis P; De Giorgi V; Cossu A; Palmieri G; Massi D
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205480
[TBL] [Abstract][Full Text] [Related]
25. The dermal-based borderline melanocytic tumor: a categorical approach.
Magro CM; Crowson AN; Mihm MC; Gupta K; Walker MJ; Solomon G
J Am Acad Dermatol; 2010 Mar; 62(3):469-79. PubMed ID: 20159313
[TBL] [Abstract][Full Text] [Related]
26. Histopathological and Molecular Features of a Conjunctival Caruncular Deep Penetrating Nevus.
van Ipenburg JA; Damman J; Paridaens D; Verdijk RM
Ocul Oncol Pathol; 2020 Aug; 6(4):293-296. PubMed ID: 33005620
[TBL] [Abstract][Full Text] [Related]
27. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
[TBL] [Abstract][Full Text] [Related]
28. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
29. Combination of Congenital and Deep Penetrating Nevus by Acquisition of β-Catenin Activation.
Garrido MC; Nájera L; Navarro A; Huerta V; Garrido E; Rodriguez-Peralto JL; Requena L
Am J Dermatopathol; 2020 Dec; 42(12):948-952. PubMed ID: 32568834
[TBL] [Abstract][Full Text] [Related]
30. The plexiform spindle cell nevus nevi and atypical variants: report of 128 cases.
Hung T; Yang A; Mihm MC; Barnhill RL
Hum Pathol; 2014 Dec; 45(12):2369-78. PubMed ID: 25300464
[TBL] [Abstract][Full Text] [Related]
31. Current diagnostic problems in melanoma pathology.
Ruiter DJ; van Dijk MC; Ferrier CM
Semin Cutan Med Surg; 2003 Mar; 22(1):33-41. PubMed ID: 12773012
[TBL] [Abstract][Full Text] [Related]
32. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.
Tan JM; Lin LL; Lambie D; Flewell-Smith R; Jagirdar K; Schaider H; Sturm RA; Prow TW; Soyer HP
JAMA Dermatol; 2015 Apr; 151(4):417-21. PubMed ID: 25607474
[TBL] [Abstract][Full Text] [Related]
33. Utilization of polarized microscopy to differentiate deep penetrating nevus from equine type melanomas.
Cleaver N; Parikh K; Kazlouskaya V; Elston D
J Cutan Pathol; 2016 Apr; 43(4):362-6. PubMed ID: 26762968
[TBL] [Abstract][Full Text] [Related]
34. Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes.
Busam KJ; Sung J; Wiesner T; von Deimling A; Jungbluth A
Am J Surg Pathol; 2013 Feb; 37(2):193-9. PubMed ID: 23026932
[TBL] [Abstract][Full Text] [Related]
35. Immunophenotype and possible origin of nevi with phenotypical heterogeneity.
Winnepenninckx V; van den Oord JJ
Arch Dermatol Res; 2004 Jul; 296(2):49-53. PubMed ID: 15141316
[TBL] [Abstract][Full Text] [Related]
36. Melanocytic Neoplasms With MAP2K1 in Frame Deletions and Spitz Morphology.
Sunshine JC; Kim D; Zhang B; Compres EV; Khan AU; Busam KJ; Gerami P
Am J Dermatopathol; 2020 Dec; 42(12):923-931. PubMed ID: 33289976
[TBL] [Abstract][Full Text] [Related]
37. The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions.
Kazakov DV; Kutzner H; Rütten A; Michal M; Requena L; Burg G; Dummer R; Kempf W
Am J Dermatopathol; 2004 Apr; 26(2):102-7. PubMed ID: 15024190
[TBL] [Abstract][Full Text] [Related]
38. Ataxia telangiectasia-mutated gene is a possible biomarker for discrimination of infiltrative deep penetrating nevi and metastatic vertical growth phase melanoma.
Roesch A; Becker B; Bentink S; Spang R; Vogl A; Hagen I; Landthaler M; Vogt T
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2486-90. PubMed ID: 18006941
[TBL] [Abstract][Full Text] [Related]
39. Combined deep penetrating nevi of the conjunctiva are relatively common lesions characterised by BRAFV600E mutation and activation of the beta catenin pathway: a clinicopathological analysis of 34 lesions.
Šekoranja D; Vergot K; Hawlina G; Pižem J
Br J Ophthalmol; 2020 Jul; 104(7):1016-1021. PubMed ID: 31558492
[TBL] [Abstract][Full Text] [Related]
40. Cutaneous melanocytic lesions: do not miss the invisible gorilla.
Prieto VG
Adv Anat Pathol; 2012 Jul; 19(4):263-9. PubMed ID: 22692289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
